Alberto M. Martelli

There are 6 included publications by Alberto M. Martelli :

TitleDateViewsBrief Description
PKR Regulates B56 alpha-mediated BCL2 Phosphatase Activity in Acute Lymphoblastic Leukemia-derived REH Cells 2011 690184 Protein phosphatase 2A (PP2A) is a heterotrimer comprising catalytic scaffold and regulatory (B) subunits. There are at least 21 B subunit family members. Thus PP2A is actually a family of enzymes defined by which B subunit is used. The B56 family me...
Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia 2011 690184 Constitutively activated AKT kinase is a common feature of T-cell acute lymphoblastic leukemia (T-ALL). Here we report that the novel AKT inhibitor (2S)-1-(1H-indol-3-yl)-3-[5-(3-methyl-2Hindazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) leads to ...
Roles of the RAF/MEK/ERK Pathway in Cell Growth Malignant Transformation and Drug Resistance 2011 690184 Growth factors and mitogens use the Ras/Raf/MEK/ERK signaling cascade to transmit signals from their receptors to regulate gene expression and prevent apoptosis. Some components of these pathways are mutated or aberrantly expressed in human cancer (e...
Synergistic Proapoptotic Activity of Recombinant Trail Plus the AKT Inhibitor Perifosine in Acute Myelogenous Leukemia Cells 2011 690184 To potentiate the response of acute myelogenous leukemia (AML) cells to TNF-Related Apoptosis- Inducing Ligand (TRAIL) cytotoxicity we have examined the efficacy of a combination with perifosine a novel phosphatidylinositol 3-kinase (PI3K)/Akt signal...
Targeting prostate cancer based on signal transduction and cell cycle pathways 2011 690184 Prostate cancer remains a leading cause of death in men despite increased capacity to diagnose at earlier stages. After prostate cancer has become hormone independent which often occurs after hormonal ablation therapies it is difficult to effectively...
Targeting the RAF/MEK/ERK PI3K/AKT and P53 pathways in hematopoietic drug resistance 2011 690184